Optical imaging developer VisEn Medical of Bedford, MA, has acquired fluorescence imaging agent intellectual property portfolios and related technology from Bayer Schering Pharma of Berlin.
The acquisition includes more than 45 issued patents worldwide covering a range of fluorescence agent constructs and imaging methods, consolidating VisEn's patent and technology resources for fluorescence imaging from preclinical research through clinical molecular diagnostics.
With the acquisition, VisEn's intellectual property portfolio covering fluorescence imaging agents now consists of more than 150 patents and patent applications. Included in the acquired portfolio are patents covering physiologic agents, bioconjugates and targeted fluorescence agents, and activatable imaging agents for measuring diverse biomarker activity in living systems, VisEn said.
Related Reading
VisEn launches imaging agent, January 19, 2010
VisEn debuts new molecular imaging agents, November 20, 2009
VisEn debuts molecular agent, FMT systems, September 24, 2009
VisEn launches fluorescence agent, September 2, 2009
VisEn expands product line, April 21, 2009
Copyright © 2010 AuntMinnie.com
